RDHL NASDAQ
RedHill Biopharma Ltd.
1W: +0.0%
1M: -32.5%
3M: -36.7%
YTD: -51.5%
1Y: -80.2%
3Y: -96.8%
5Y: -100.0%
$0.50
+0.02 (+4.17%)
Weekly Expected Move ±10.1%
$0
$0
$0
$1
$1
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Revenue Segmentation
By Product / Service
Income Trends
Revenue
$8M
+23.2% ▲
5Y CAGR: +5.0%
Gross Profit
$5M
+58.0% ▲
5Y CAGR: +3.8%
Operating Income
-$15M
-215.7% ▼
Net Income
-$8M
-134.6% ▼
EPS (Diluted)
$-7.00
-115.2% ▼
EBITDA
-$8M
-128.9% ▼
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| Revenue | $64M | $86M | $62M | $7M | $8M |
| YoY Growth | +923.0% | +33.2% | -27.9% | -89.4% | +23.2% |
| Cost of Revenue | $37M | $49M | $33M | $3M | $3M |
| Gross Profit | $27M | $36M | $28M | $3M | $5M |
| Gross Margin | 42.7% | 42.4% | 46.1% | 47.0% | 60.3% |
| R&D Expenses | $16M | $29M | $7M | $4M | $2M |
| SG&A Expenses | $75M | $88M | $64M | $31M | $16M |
| Operating Expenses | $91M | $117M | $71M | -$10M | $19M |
| Operating Income | -$64M | -$81M | -$43M | $13M | -$15M |
| Operating Margin | -99.0% | -94.6% | -69.3% | 193.4% | -181.7% |
| Interest Expense | $12M | $17M | $41M | $367K | $55K |
| Income Before Tax | -$76M | -$98M | -$72M | $24M | -$8M |
| Tax Expense | $0 | $0 | $0 | $0 | $0 |
| Net Income | -$76M | -$98M | -$72M | $24M | -$8M |
| Net Margin | -118.4% | -114.0% | -116.0% | 366.2% | -102.8% |
| EPS (Diluted) | $-1000.00 | $-1000.00 | $-600.00 | $46.00 | $-7.00 |
| EBITDA | -$55M | -$63M | -$22M | $26M | -$8M |
| Shares Outstanding | 72854 | 93054 | 123858 | 518244 | 2M |